|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
NKT Therapeutics Closes Series A Venture Round Led by SV Life Sciences and MedImmune Ventures
March 16th, 2009 No comments
Company Targeting Natural Killer T Cells as Approach to Treating Inflammatory Diseases
NEWTON, Mass. NKT Therapeutics, Inc., a privately held biotechnology company, today announced that it has closed an $8M Series A venture financing co-led by SV Life Sciences (SVLS) and MedImmune Ventures. As part of the transaction, Michael Ross, Ph.D., Managing Partner at SVLS, and Joseph Amprey, M.D., Ph.D., Senior Managing Director of MedImmune Ventures, joined the NKT Therapeutics board.
“Natural Killer T (NKT) cells play a pivotal role in human health and disease, controlling the type and magnitude of the body’s innate immune response against infectious agents and cancer, as well as the undesirable immune reactions associated with asthma and autoimmune diseases,” said Dr. Ross. “Thus by selectively activating or depleting NKT function, NKT Therapeutics’ approach has the potential to treat a wide range of important diseases as well as provide new avenues for vaccine creation.”
“Based on its strong understanding of this unique area of biology, NKT has already created an early-stage pipeline of therapeutic leads against multiple targets,” commented Dr. Amprey. “With asthma selected as the lead program and a specific anti-NKT antibody in pre-IND development, we look forward to seeing the company build a portfolio of exciting product candidates for opportunities that can help address important medical needs.”
“I am very excited to lead the development of this very promising technology, whose broad potential for addressing major health care needs is underscored by this successful financing,” said Robert Mashal, M.D., NKT Therapeutics President and Chief Executive Officer.
NKT Therapeutics has licensed an extensive intellectual property portfolio from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. This IP is based on the work of the company’s three scientific co-founders – Steven Balk, M.D. Ph.D., Associate Professor, Division of Oncology; S. Brian Wilson, M.D. Ph.D., Assistant Professor of Medicine, MGH Diabetes Unit; and Mark Exley, Ph.D., Assistant Professor of Medicine, Division of Immunology. The Company’s scientific co-founders are all faculty members of Harvard Medical School.
About SV Life Sciences
SV Life Sciences is a venture capital adviser and manager that makes selected investments in businesses with experienced entrepreneurs and management teams. SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.6 billion that primarily invest amounts of between $1m and $20m in North America and Europe, but will consider innovative investments in other regions. SV Life Sciences team of 34 professionals has a diverse, complimentary set of skills and experience that allow SV Life Sciences to tailor a team to work with almost any life sciences business. SVLS was established in 1993 and currently has offices in Boston, San Francisco and London. For more information, please visit the company’s website at http://www.svlsa.com.
About MedImmune Ventures
MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies. MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to AstraZeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease. For more information, please visit http://www.medimmune.com/ventures/overview.asp.
About NKT Therapeutics, Inc.
NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company’s mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis. For more information on the company, please visit http://www.nktrx.com.
Source: NKT Therapeutics, Inc.
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility